HCC with PVTT: Liver Cancer | April 2026

Introduction

Hepatocellular carcinoma with portal vein tumor thrombus represents one of the most aggressive forms of liver cancer, associated with poor prognosis and limited survival. Standard treatment relies on systemic therapy, including targeted agents and immunotherapy, but outcomes remain suboptimal. Increasingly, combining systemic therapy with locoregional approaches such as transarterial chemoembolization or hepatic arterial infusion chemotherapy is being explored to improve disease control.

Problem Statement

Systemic therapy alone provides limited survival benefit in HCC with PVTT, and the role of combined locoregional and systemic treatment strategies is not well established.

Summary

This propensity score–matched study demonstrates that combining locoregional therapy (TACE or HAIC) with systemic therapy significantly improves outcomes compared to systemic therapy alone in patients with HCC and PVTT. The combination approach nearly tripled median overall survival (15.7 vs. 5.9 months) and significantly improved progression-free survival and disease control rates.

Importantly, the survival benefit was particularly pronounced in patients with advanced PVTT (Vp4) and those with poorer liver function (Child-Pugh B), suggesting that this strategy may be especially valuable in high-risk groups. Although adverse events were more frequent with combination therapy, severe toxicities were comparable between groups, indicating acceptable safety.

Clinically, this study supports a shift toward multimodal therapy in advanced HCC with vascular invasion. It challenges the traditional reliance on systemic therapy alone and suggests that integrating locoregional approaches can meaningfully improve survival in selected patients.